{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:10:14Z","timestamp":1778253014107,"version":"3.51.4"},"reference-count":41,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403861"],"award-info":[{"award-number":["82403861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["CXZX202234"],"award-info":[{"award-number":["CXZX202234"]}]},{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["22KJA320004"],"award-info":[{"award-number":["22KJA320004"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20241039"],"award-info":[{"award-number":["BK20241039"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renal carcinoma remains a highly lethal malignancy, and tumor vaccine efficacy is frequently hampered by a profoundly immunosuppressive tumor microenvironment. V-domain Ig suppressor of T-cell activation (VISTA), an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells (Tregs), represents a critical barrier to effective antitumor immunity. Targeting VISTA may therefore provide a promising strategy to overcome immune suppression and enhance tumor vaccine efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Recombinant adenoviral vaccines encoding carbonic anhydrase IX (CAIX) and VISTA (Ad-CAIX and Ad-VISTA) were constructed and validated for efficient antigen expression. The antitumor efficacy of Ad-VISTA\/CAIX co-immunization was evaluated in subcutaneous, lung metastatic, orthotopic, and anti-programmed cell death protein 1-resistant renal carcinoma models. Vaccine-induced immune responses were assessed by flow cytometry, immunohistochemistry, ELISA, cell proliferation assays, cytotoxic T lymphocyte (CTL) assays, and in vivo immune cell depletion experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ad-VISTA immunization markedly potentiated the therapeutic efficacy of CAIX-targeted vaccination, resulting in significant tumor growth inhibition and prolonged survival across multiple renal carcinoma models. Mechanistically, VISTA-targeting remodeled the tumor microenvironment by enhancing the infiltration and activation of dendritic cells (DCs) and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells while reducing immunosuppressive myeloid cells and Tregs. Ad-VISTA\/CAIX co-immunization promoted the expansion and maturation of multiple DC subsets, characterized by increased expression of CD40, CD80, CD86, and major histocompatibility complex molecules, thereby facilitating efficient antigen presentation. VISTA immunization elicited robust antigen-specific antibody and neutralizing responses, restored CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell proliferation, and enhanced CTL-mediated tumor cell killing. Depletion of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells abrogated therapeutic efficacy of Ad-VISTA\/CAIX vaccine, establishing its essential role in tumor control. Furthermore, combined vaccination induced durable memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses capable of preventing tumor recurrence on rechallenge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These results indicated that vaccine-induced VISTA blockade effectively amplifies DC-mediated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell immunity and synergistically enhances tumor vaccine efficacy. Targeting VISTA represents a promising immunotherapeutic strategy for improving vaccine-based treatments in renal carcinoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015052","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:15Z","timestamp":1778249715000},"page":"e015052","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma"],"prefix":"10.1136","volume":"14","author":[{"given":"Jiawei","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Oncology, Ninghe District Hospital of Tianjin, Tianjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haomin","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Lu","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxiang","family":"Shao","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1963-4236","authenticated-orcid":false,"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Fang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-8109","authenticated-orcid":false,"given":"Huizhong","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Neeli","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology and Cancer Biology and Evolution Program, H Lee Moffitt Cancer Center and Research Institute Department of Molecular Oncology, Tampa, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6020-7263","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8028-2954","authenticated-orcid":false,"given":"Dafei","family":"Chai","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026050807150694000_14.5.e015052.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00046-X"},{"key":"2026050807150694000_14.5.e015052.2","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026050807150694000_14.5.e015052.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0210-z"},{"key":"2026050807150694000_14.5.e015052.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3323"},{"key":"2026050807150694000_14.5.e015052.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0282-3"},{"key":"2026050807150694000_14.5.e015052.6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026050807150694000_14.5.e015052.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.001"},{"key":"2026050807150694000_14.5.e015052.8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biopha.2017.03.015","article-title":"Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4)","volume":"90","author":"Zhao","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2026050807150694000_14.5.e015052.9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature New Biol"},{"key":"2026050807150694000_14.5.e015052.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0"},{"key":"2026050807150694000_14.5.e015052.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420370112"},{"key":"2026050807150694000_14.5.e015052.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619"},{"key":"2026050807150694000_14.5.e015052.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2169-1"},{"key":"2026050807150694000_14.5.e015052.14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","article-title":"VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance","volume":"11","author":"Schaafsma","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026050807150694000_14.5.e015052.15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature New Biol"},{"key":"2026050807150694000_14.5.e015052.16","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13001"},{"key":"2026050807150694000_14.5.e015052.17","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03701-w","article-title":"The VISTA\/VSIG3\/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma","volume":"73","author":"Olbromski","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026050807150694000_14.5.e015052.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1311658","article-title":"A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"14","author":"Iadonato","year":"2023","journal-title":"Front Immunol"},{"key":"2026050807150694000_14.5.e015052.19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003382","article-title":"Rationally targeted anti-VISTA antibody that blockades the C-C\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner","volume":"10","author":"Thakkar","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026050807150694000_14.5.e015052.20","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1578","article-title":"Blockade of V\u2010domain immunoglobulin suppressor of T\u2010cell activation reprograms tumour\u2010associated macrophages and improves efficacy of PD\u20101 inhibitor in gastric cancer","volume":"14","author":"Cao","year":"2024","journal-title":"Clinical & Translational Med"},{"key":"2026050807150694000_14.5.e015052.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026050807150694000_14.5.e015052.22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/bph.17404","article-title":"V-domain immunoglobulin suppressor of T-cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma","volume":"182","author":"Jin","year":"2025","journal-title":"Br J Pharmacol"},{"key":"2026050807150694000_14.5.e015052.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07006.x"},{"key":"2026050807150694000_14.5.e015052.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00706-x","article-title":"The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma","volume":"8","author":"Jiang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026050807150694000_14.5.e015052.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010521","article-title":"Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma","volume":"13","author":"Zheng","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026050807150694000_14.5.e015052.26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0832"},{"key":"2026050807150694000_14.5.e015052.27","doi-asserted-by":"crossref","first-page":"138515","DOI":"10.1016\/j.ijbiomac.2024.138515","article-title":"Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma","volume":"286","author":"Lu","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"2026050807150694000_14.5.e015052.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203468109"},{"key":"2026050807150694000_14.5.e015052.29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14420"},{"key":"2026050807150694000_14.5.e015052.30","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-3"},{"key":"2026050807150694000_14.5.e015052.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.12.013"},{"key":"2026050807150694000_14.5.e015052.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2025-000854","article-title":"First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours","volume":"5","author":"Gomez-Roca","year":"2026","journal-title":"BMJ Oncol"},{"key":"2026050807150694000_14.5.e015052.33","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s00259-024-06854-z","article-title":"Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with (89)Zr-labelled CI-8993","volume":"51","author":"Burvenich","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026050807150694000_14.5.e015052.34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41416-025-03013-5","article-title":"Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA","volume":"133","author":"Abudula","year":"2025","journal-title":"Br J Cancer"},{"key":"2026050807150694000_14.5.e015052.35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1504"},{"key":"2026050807150694000_14.5.e015052.36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0507"},{"key":"2026050807150694000_14.5.e015052.37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13238-019-0642-z","article-title":"Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy","volume":"10","author":"Hong","year":"2019","journal-title":"Protein Cell"},{"key":"2026050807150694000_14.5.e015052.38","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1007\/s00432-022-04329-y","article-title":"Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus","volume":"149","author":"Zapa\u0142a","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026050807150694000_14.5.e015052.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02494-y"},{"key":"2026050807150694000_14.5.e015052.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"2026050807150694000_14.5.e015052.41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1464-410X.2008.07645.x","article-title":"Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies","volume":"101 Suppl 4","author":"Shuch","year":"2008","journal-title":"BJU Int"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:18Z","timestamp":1778249718000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2026-015052"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015052","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}